Skip to content
OpenCapital
Get started

Bio-Techne TECH Recovery Of Assets Held For Sale

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$9.07B-11.8%
Enterprise value$9.15B-13.6%
P/E60.6×+13.6×
P/S7.5×-1.0×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept tech:RecoveryOfAssetsHeldForSale.

The official record: Bio-Techne’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's recovery of assets held for sale.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Techne's recovery of assets held for sale?
Bio-Techne (TECH) reported recovery of assets held for sale of $6.79M in Q3 2025.